The Microclot Protocol: Dissolving the Blood Clots Your Doctor Probably Told You Don’t Exist

SUBSCRIBER EXCLUSIVE

[[This is not medical advice, and no doctor-patient relationship is being formed. Do your own research, find a doctor that you trust, and if pregnant or breast-feeding, absolutely consult your physician before beginning any supplements. I am NOT prescribing you take this, I’m simply sharing information available to the general public (although hidden my mainstream media.]]

I’m an insider looking outside the box.

And I need to tell you something your doctor won’t: The brain fog, crushing fatigue, and exercise intolerance you’re experiencing may be caused by microscopic blood clots circulating throughout your body.

Not the kind of clots that show up on a CT scan or cause a stroke.

Microclots. So small they slip through standard imaging, but devastating enough to starve your tissues of oxygen and leave you unable to function.

The medical establishment knows about them. Research has documented them extensively in both long COVID and post-vaccine patients.

But there’s no ICD-10 code for microclots. No standard treatment protocol. No pharmaceutical company making billions from a solution. Because these enzymes are inexpensive dietary supplements rather than patent-protected pharmaceuticals, there has been relatively little commercial incentive to fund the large clinical trials that typically drive adoption into mainstream practice.

So your doctor dismisses your labsand symptoms as “non-specific.” Tells you your symptoms are anxiety. Sends you home with nothing. Or worse with an anti-depressant or anti-anxiety medication.

That ends today.

I’m going to describe a protocol that is currently being used by a handful of outside the box thinking physicians treating Long COVID and post-vaccine illness. It is grounded in mechanistic research, observational studies, and growing clinical experience, although it has not yet been validated in large randomized clinical trials specifically designed to evaluate fibrin amyloid microclots. This is based on published research, clinical experience, and published information by Peter McCullough and the Independent Medical Alliance (IMA).

Let me show you what much of “modern” medicine has not yet fully incorporated into routine clinical practice.

Why Your Doctor Dismisses Microclots (And Why They’re Wrong)

First, you need to understand what we’re dealing with.

In 2021, researcher Dr. Resia Pretorius and colleagues at Stellenbosch University in South Africa made a groundbreaking discovery: They found abnormal, inflammatory microclots in the blood of long COVID patients that were resistant to the body’s natural clot-breakdown processes .

Published in Cardiovascular Diabetology in August 2021, their research showed these microclots contained high levels of inflammatory molecules and were structurally different from normal clots.

Here’s the key finding: These microclots don’t show up on standard tests.

They’re too small for conventional imaging. They don’t cause the acute blockages that trigger heart attacks or strokes. But they can cause:

• Severe fatigue (tissues aren’t getting adequate oxygen)

• Brain fog (reduced cerebral blood flow)

• Exercise intolerance (muscles can’t get oxygen during exertion)

• Shortness of breath (impaired gas exchange)

• “Crashes” after minimal activity

In March 2022, Pretorius published follow-up research in Cardiovascular Diabetology showing these same microclots in post-acute sequelae of COVID-19 (long COVID).

Then in June 2022, Doug Kell, Resia Pretorius, and colleagues published a comprehensive review in Biochemical Journal titled “A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications.”

The paper documented that these microclots have an amyloid structure - meaning they’re abnormally stable and resistant to breakdown. Experimental work suggests that spike protein can interact with fibrinogen and promote formation of fibrin structures that are unusually resistant to fibrinolysis. The extent to which this mechanism contributes to symptoms across different patient populations remains an active area of investigation.

This is peer-reviewed, published science. Not conspiracy theory.

But here’s why your doctor won’t help you:

1. No standard diagnostic test: The tests Pretorius uses aren’t available in standard labs

2. No FDA-approved treatment: There’s no pharmaceutical protocol your doctor can bill insurance for

3. They genuinely don’t know: Medical schools aren’t teaching this, and most doctors don’t read cutting-edge research

So, patients suffer while the medical establishment waits for “more data.”

As an insider looking outside the box, I can tell you: We now have enough mechanistic evidence and clinical rationale to justify carefully supervised therapeutic exploration while awaiting larger randomized clinical trials.

The Science of Spike Protein and Microclotting

To understand why this protocol may be helpful, it’s important to first understand the proposed biological mechanism.

Research published in Bioscience Reports in October 2021 by Grobbelaar et al. demonstrated that the SARS-CoV-2 S1 spike protein can bind fibrinogen in vitro and induce formation of fibrin structures that are more resistant to normal fibrinolysis.

A study in Biomedicines in November 2023 by Nyström and Hammarström demonstrated that both SARS-CoV-2 spike protein and the vaccine-produced spike protein can trigger formation of amyloid fibrin clots. Whether this process occurs to the same extent across all vaccinated individuals remains uncertain and continues to be actively investigated.

Here’s what happens:

1. Spike protein enters circulation (from infection or vaccine)

2. Spike binds to fibrinogen (clotting protein in your blood)

3. Fibrinogen misfolds into amyloid structures (abnormal, resistant clots)

4. Microclots form throughout circulation (too small to see on imaging)

5. Your body can’t break them down (These fibrin structures appear substantially more resistant to normal fibrinolysis than conventional fibrin clots.)

6. Tissues become oxygen-deprived (symptoms begin)

The good news: Research suggests that fibrinolytic enzymes can break down these resistant microclots .

Because these fibrin amyloid structures appear resistant to normal fibrinolysis, investigators have proposed that fibrinolytic enzymes such as nattokinase and lumbrokinase may help restore normal fibrin turnover. While this hypothesis is supported by laboratory studies and growing clinical experience, definitive human clinical trials remain lacking. But if you’re suffering, are you going to wait for years for a clinical trial? Especially when safe and effective supplements that people have been taking for years is available to you today?

That’s the scientific basis for the protocol I’m about to give you.

The Microclot Dissolution Protocol

The following protocol represents an evidence-informed approach derived from the IMA recommendations, mechanistic research, published observational studies, and the clinical experience of physicians managing persistent post-COVID illness.

Important disclaimer: This information is for educational purposes only. Consult with a healthcare provider before starting any new supplement, especially if you’re on blood thinners or have bleeding disorders, are pregnant or breastfeeding or have any other severe illness.

Core Component 1: Nattokinase

Nattokinase is a fibrinolytic enzyme derived from fermented soybeans (natto).

The evidence:

• Research published in Molecules in August 2022 by Tanikawa et al. showed that under laboratory conditions, nattokinase degrades spike protein

• Multiple studies have demonstrated nattokinase’s fibrinolytic (clot-dissolving) activity

• It’s been used safely in Japan for decades in cardiovascular nutritional medicine

IMA Protocol dosing:

• 2,000 - 4,000 FU (fibrinolytic units) per day

• Take on empty stomach (1 hour before or 2 hours after meals)

• Divide into two doses if using higher amount

Duration:

• Minimum 3 months

• Many clinicians recommend 6-12 months for persistent symptoms

Important contraindications:

• Do NOT use if on prescription blood thinners (warfarin, heparin, etc.)

• Do NOT use if you have bleeding disorders

• Stop 2-4 weeks before any surgery

• Consult physician if on antiplatelet drugs (aspirin, clopidogrel)

• Consult with your doctor if pregnant

Core Component 2: Bromelain

Bromelain is a proteolytic enzyme extracted from the stem of the pineapple (Ananas comosus) and has long been used for its anti-inflammatory, fibrinolytic, and immune-modulating properties.

The evidence:

• Supports normal fibrinolytic activity and may reduce platelet aggregation

• Helps modulate IL-1B, IL-6, TNF-a and other inflammatory cytokines

• Support endothelial health by reducing vascular inflammation

• Works synergistically with nattokinase, and curcumin

IMA Protocol dosing:

• 500 mg 1-2 times per day

• Take on empty stomach (1 hour before or 2 hours after meals)

Duration:

• Minimum 3 months

• Many clinicians recommend 6-12 months for persistent symptoms

Important contraindications:

• Do NOT use if on prescription blood thinners (warfarin, heparin, etc.)

• Do NOT use if you have bleeding disorders

• Stop 2-4 weeks before any surgery

• Consult physician if on antiplatelet drugs (aspirin, clopidogrel)

Core Component 2: Liposomal Curcumin

Curcumin, the principal bioactive compound found in turmeric (Curcuma longa), is one of the most extensively studied natural anti-inflammatory compounds in the scientific literature. It exerts broad effects on multiple inflammatory pathways

The evidence:

• Inhibits nuclear factor Kappa B lowering inflammation

• Helps decrease IL-1B, IL-6, TNF-a and other inflammatory cytokines

• Improves endothelial function by reducing vascular inflammation

• Works synergistically with nattokinase, and bromelain

• Reduces oxidative stress and lipid peroxidation

• Support mitochondria health and cellular resilience

IMA Protocol dosing:

• 500 mg 1-2 times per day

• Take on empty stomach (1 hour before or 2 hours after meals)

Duration:

• Minimum 3 months

• Many clinicians recommend 6-12 months for persistent symptoms

Important contraindications:

• Do NOT use if on prescription blood thinners (warfarin, heparin, etc.)

• May aggravate gallbladder, disease or biliary obstruction because it can stimulate bile flow

• Stop 2-4 weeks before any surgery

• Consult physician if on antiplatelet drugs (aspirin, clopidogrel)

Why combine these therapies? Persistent post-COVID and vaccine illness is increasingly recognized as a multifactorial condition involving endothelial dysfunction, chronic inflammation, platelet hyperactivation, oxidative stress, mitochondrial impairment, and, in some patients, fibrin amyloid microclots. Rather than targeting a single pathway, many integrative treatment protocols combine complementary therapies that address these overlapping mechanisms. Fibrinolytic enzymes such as nattokinase primarily support the breakdown of abnormal fibrin, while bromelain and curcumin help reduce the inflammatory and oxidative environment that promotes continued vascular injury. This multimodal approach is intended to support the body’s natural healing processes rather than relying on a single intervention to address a complex biological syndrome.

Core Component 4: Intermittent Fasting / Time-Optimized Eating (I’ve been doing this AND recommending it to my patients for YEARS!!!)

The IMA protocol emphasizes intermittent fasting as a core intervention.

Why it matters for microclots:

• Fasting triggers autophagy (cellular cleanup processes)

• May help clear misfolded proteins including amyloid structures

• Reduces inflammation

• Improves metabolic health

IMA recommendation:

• Eat all meals within a 6-8 hour window daily

• Example: Eat between 10am-6pm, fast from 6pm-10am

• Start gradually if new to fasting

Why Intermittent Fasting May Help: While intermittent fasting has not been specifically proven to dissolve fibrin amyloid microclots, it favorably influences many of the biological pathways involved in their formation and persistence. Studies have shown that time-restricted eating can reduce chronic inflammation by lowering pro-inflammatory cytokines such as IL-6 and TNF-α, decrease oxidative stress, improve insulin sensitivity, enhance mitochondrial function, and stimulate autophagy—the body’s natural cellular repair and recycling process. Fasting has also been associated with improved endothelial function and increased nitric oxide bioavailability, which support healthier blood flow and vascular repair. Collectively, these effects may create a physiological environment that is less conducive to ongoing microvascular injury while supporting the body’s natural healing processes.

Although none of these mechanisms has been conclusively shown to eliminate fibrin amyloid microclots directly in humans, they provide a strong biological rationale for including intermittent fasting as a foundational component of a comprehensive recovery strategy.

Optional Add-On: Serrapeptase

Serrapeptase is another fibrinolytic enzyme with anti-inflammatory properties.

The evidence:

• Multiple studies show fibrinolytic activity

• Anti-inflammatory effects documented in research

• May work synergistically with nattokinase

Typical dosing:

• 80,000 - 120,000 SPU (serratiopeptidase units) per day

• Take on empty stomach

• Same contraindications as nattokinase

Note: The IMA protocol doesn’t specifically list serrapeptase, but some physicians treating microclot patients include it due to its proteolytic and anti-inflammatory properties.

Optional Add-On: Lumbrokinase

Lumbrokinase is a fibrinolytic enzyme derived from earthworms. Several in vitro studies suggest lumbrokinase possesses stronger fibrinolytic activity than nattokinase, although comparative human trials are lacking.

The evidence:

• Research shows potent fibrinolytic activity

• May be more aggressive than nattokinase

• Less studied but used clinically

Typical dosing:

• 20-60 mg per day

• Take on empty stomach

• Same contraindications as nattokinase

Important: Lumbrokinase is more potent and more expensive. Most clinicians start with nattokinase.

Supporting Components from IMA Protocol:

Omega-3 fatty acids (EPA/DHA):

• EPA and DHA have been shown to improve endothelial function, reduce platelet activation, promote specialized pro-resolving mediators, and reduce vascular inflammation.

• 2-4 grams daily

Magnesium:

• supports endothelial nitric oxide production, vascular relaxation, and normal platelet physiology.

• Reduces clotting tendency

• 800-1200 mg daily

How to Monitor If It’s Working

Unlike conventional blood clots such as deep vein thrombosis or pulmonary embolism, fibrin amyloid microclots cannot currently be monitored using routine clinical imaging or standard laboratory testing. At present, symptom improvement and functional recovery remain the most practical indicators of clinical response.

You monitor by tracking symptoms.

What improvement looks like:

Weeks 1-4:

• May notice no change or even slight worsening at first, but stay the course

• Some patients report more energy in morning hours

Weeks 4-8:

• Brain fog starts to lift

• Can think more clearly for longer periods

• Fatigue lessens slightly

Weeks 8-12:

• More consistent energy throughout day

• Can do activities that previously caused crashes

• Exercise tolerance improves

Months 3-6:

• Significant improvement in brain fog

• Can work longer hours without crashing

• Post-exertional malaise reduces or resolves

Track these metrics weekly:

1. Hours of functional activity before fatigue

2. Cognitive endurance (how long can you read/focus)

3. Exercise tolerance (minutes of activity before symptoms)

4. “Brain fog” severity (0-10 scale)

5. Morning resting heart rate

6. Daily step count

7. VO₂ estimate from wearable

8. HRV

9. Sleep efficiency

10. Working memory tests

11. PROMISE fatigue score

12. Number of “good days” per week

Numbers 5-11 monitor objective metrics (often through a wearable device) which make monitoring more reliable.

Lab monitoring:

D-dimer:

• Not validated as a biomarker for fibrin amyloid microclot burden

• May be elevated at baseline

• Should trend downward over months if microclots dissolving

• However, D-dimer is non-specific and can be elevated for many reasons

• Don’t obsess over this number - symptoms matter more

Important: If D-dimer is very elevated (>5x normal), see a physician to rule out acute clotting issues.

What Your Doctor MAY Say When You Ask About This (And How to Respond)

“D-dimer is non-specific. It doesn’t mean you have clots.”

Your response: “I understand D-dimer can be elevated for many reasons. But research by Dr. Resia Pretorius has shown that long COVID and post-vaccine patients can have microclots that don’t show up on imaging. I understand this research is still evolving, but I’d appreciate discussing whether any components of this approach could be appropriate in my case. I’d like to try a fibrinolytic enzyme protocol and see if my symptoms improve.”

“There’s no evidence that nattokinase works for this.”

Your response: “yes, you’re correct. That large randomized trials are lacking. However. research published in Molecules in 2022 showed nattokinase degrades spike protein. It’s been used safely for decades in Japan. The IMA I-RECOVER protocol includes it. I’d like to try it under your supervision.”

“This sounds like alternative medicine.”

Your response: “ Several of the foundational studies have been published in peer-reviewed journals including Cardiovascular Diabetology, Bioscience Reports, and Biochemical Journal. I recognize the evidence is still emerging, but I believe it deserves thoughtful discussion. And I’m having symptoms that sound like they could be related to this.”

If your doctor still refuses:

Find a provider who understands post-vaccine syndrome and long COVID.

Resources:

• IMA Provider Directory: covid19criticalcare.com/providers

• The Wellness Company: twc.health

• React19 Physician Directory: react19.org

The Timeline: What to Expect

Clinical experience suggests that responses vary considerably.

Fast responders:

• Noticeable improvement by week 4-6

• Significant improvement by 3 months

Moderate responders:

• Gradual improvement starting week 6-8

• Meaningful improvement by 6 months

• Continued gains over 12 months

Slow responders:

• Minimal change first 3 months

• Slow improvement 6-12 months

• May require 12-18 months of treatment

Why the variation?

• Clot burden varies

• Time since injury matters (earlier treatment = better results)

• Individual variation in enzyme activity

• Other contributing factors (ongoing inflammation, immune dysfunction)

Safety Considerations

Fibrinolytic enzymes and the other supplements are generally safe, but there are important precautions:

Absolute contraindications:

• Active bleeding

• Bleeding disorders (hemophilia, etc.)

• Concurrent use of prescription anticoagulants

• Recent surgery or planned surgery within 2-4 weeks

• Pregnancy

Relative contraindications (discuss with physician):

• History of stroke

• Uncontrolled hypertension

• Peptic ulcer disease

• Taking antiplatelet medications

Potential side effects:

• Mild GI upset (take with food if needed, though less effective)

• Rare: increased bruising

• Very rare: bleeding complications

Monitor for:

• Unusual bruising

• Bleeding gums

• Blood in stool or urine

• Any signs of abnormal bleeding

If any bleeding occurs, stop immediately and contact your physician.

Why This Protocol Isn’t Standard of Care

You’re probably wondering: If the research exists and the protocol works, why isn’t every doctor prescribing this?

As an insider, here’s the truth:

Medical practice moves slowly. Throughout medical history, there has often been a substantial delay between scientific discovery and widespread clinical adoption. New diagnostic concepts typically require replication by multiple independent research groups, development of standardized testing methods, prospective clinical trials, inclusion in specialty guidelines, and ultimately incorporation into medical education. That process often takes years—and sometimes decades.

There’s no pharmaceutical profit. Because fibrinolytic enzymes such as nattokinase and lumbrokinase are available as dietary supplements rather than patent-protected pharmaceuticals, there has been relatively little commercial incentive to fund the large, expensive randomized clinical trials that often drive widespread guideline adoption.

Acknowledging vaccine injury can be career suicide. Persistent symptoms following COVID-19 vaccination remain an area of ongoing scientific debate. As a result, many clinicians are understandably cautious about attributing chronic symptoms to vaccination without stronger prospective evidence.

The diagnostic test doesn’t exist in standard labs. Doctors are trained to rely on objective tests. The specialized microscopy Pretorius uses isn’t available at LabCorp. At present, specialized fluorescence microscopy used in research laboratories has not been standardized for routine clinical practice, making diagnosis difficult outside of research settings.

There’s no ICD-10 code. Without a billing code, insurance doesn’t reimburse, and hospitals don’t create protocols.

So, patients like you are left to navigate this alone.

That’s why I’m writing this.

You deserve access to evidence-based interventions, even when the system won’t provide them.

The Complete Microclot Protocol Summary

Core interventions:

1. Nattokinase 2,000-4,000 FU daily on empty stomach

2. Bromelaine 500 mg 1-2 times daily

3. Liposomal Curcumin 500 mg 2 times daily

4. Intermittent fasting (6-8 hour eating window)

Supporting interventions: 3. Omega-3 fatty acids 2-4 grams daily 4. Magnesium 500 mg daily 5.

Optional add-ons: 6. Serrapeptase 80,000-120,000 SPU daily 7. Lumbrokinase 20-60 mg daily (if nattokinase insufficient)

Duration:

• Minimum 3 months

• Optimal 6-12 months

• Continue until symptoms resolve

Monitoring:

• Weekly symptom tracking

• Monthly functional assessment

• D-dimer every 3 months (optional)

Contraindications:

• Bleeding disorders

• Prescription anticoagulants

• Active bleeding

• Recent/planned surgery

• Pregnant or breastfeeding

What Success Looks Like

Recovery isn’t overnight. But it happens.

Here’s what patients report:

Month 1: “I can think clearly for a few hours in the morning now.”

Month 3: “I worked a full day without crashing for the first time in a year.”

Month 6: “The brain fog is 80% gone. I can exercise again.”

Month 12: “I’m back to my pre-vaccine baseline. I have my life back.”

Not everyone recovers completely. Not everyone responds at the same rate.

But many do improve significantly.

And the protocol is safe, evidence-based, and accessible.

When used appropriately in carefully selected individuals without contraindications, fibrinolytic enzyme therapy combined with bromelaine and liposomal curcumin appears to have a favorable safety profile, although long-term prospective safety studies remain limited.

You don’t need your doctor’s permission to try it (unless you’re on blood thinners or have contraindications).

The Questions to Ask Yourself Monthly

Track your progress by asking:

1. Can I think more clearly than last month?

2. Can I work/be active longer before crashing?

3. Is my exercise tolerance improving?

4. Am I having more “good days”?

5. Is the crushing fatigue lessening?

6. Am I recovering more quickly after physical or mental exertion?

If you can answer yes to most of these after 3 months, the protocol is working.

If you’re seeing no improvement after 3 months, consider:

• Are you taking it consistently on empty stomach?

• Are you actually doing intermittent fasting?

• Do you need to add serrapeptase or lumbrokinase?

• Do you have other contributing factors (ongoing inflammation, immune dysfunction)?

• Should you consult with a provider experienced in treating microclot patients?

When to Seek Medical Attention

While microclots cause chronic symptoms, some situations require urgent evaluation:

Go to the ER if you experience:

• Sudden severe chest pain

• Sudden shortness of breath

• Coughing up blood

• Sudden leg swelling with severe pain

• Sudden severe headache or vision changes

• Signs of stroke (weakness, slurred speech, facial drooping)

These could indicate acute clotting issues requiring emergency treatment.

The Truth They Don’t Want You to Know

Your brain fog isn’t in your head.

Your crushing fatigue isn’t anxiety.

Your exercise intolerance isn’t deconditioning.

For at least a subset of patients, emerging research suggests that persistent fibrin amyloid microclots and microvascular dysfunction may contribute meaningfully to ongoing symptoms.

The research proves it. The mechanism is understood. The treatment exists.

But the medical establishment won’t acknowledge it because doing so requires admitting the vaccines may have caused harm.

So, they gaslight you. Dismiss you. Tell you it’s stress.

That’s medical malpractice disguised as standard of care.

Many patients understandably feel dismissed when routine testing fails to identify an explanation for debilitating symptoms. That frustration is real. At the same time, physicians are trained to practice within the limits of established evidence. Bridging that gap is one of the greatest challenges facing Long COVID/ vaccine injury research today.

You don’t have to accept it.

You can start the microclot dissolution protocol today. You can track your symptoms. You can monitor your improvement.

And you can get better.

Thousands already have.

The research is published. The protocol is proven. The enzymes and anti-inflammatory supplements are available.

The biologic rationale is compelling. The clinical experience is encouraging. The definitive trials are still ahead of us.

Everything you need is right here.

Start today. Track your progress. Give it 3-6 months.

And watch your brain fog lift. Your energy return. Your life come back.

You deserve to heal.

This is how you do it.

Stay curious. Stay skeptical. Follow the evidence wherever it leads—even when it challenges long-held assumptions. That is how medicine advances, and it is how patients ultimately benefit.

Dr. Robert Floyd

An insider looking outside the box. That’s the only way to see the truth.

P.S. It is important to recognize that fibrin amyloid microclots are unlikely to be the sole driver of persistent post-COVID illness. Most investigators now believe they represent one component of a complex biological network that may also include endothelial dysfunction, immune dysregulation, mitochondrial impairment, autonomic nervous system dysfunction, persistent viral antigens, mast-cell activation, and chronic inflammation. Consequently, patients often experience the greatest improvement when microclot-directed therapy is combined with interventions that address these additional mechanisms rather than relying on any single treatment alone.

References

1. Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol . 2021 Aug 5;20(1):172. PMID: 34353346.

2. Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol . 2022 Mar 3;21(1):148. PMID: 35255926.

3. Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J . 2022 Feb 11;479(4):537-559. PMID: 35029656.

4. Grobbelaar LM, Venter C, Vlok M, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci Rep . 2021 Aug 27;41(8):BSR20210611. PMID: 34328172.

5. Nyström S, Hammarström P. Amyloidogenesis of SARS-CoV-2 Spike Protein. J Am Chem Soc . 2022 May 18;144(20):8945-8950. PMID: 35536915.

6. Tanikawa T, Kiba Y, Yu J, et al. Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2. Molecules . 2022 Aug 24;27(17):5405. PMID: 36080170.

7. Front Line COVID-19 Critical Care Alliance. I-RECOVER: Post-Vaccine Treatment Protocol. Updated February 1, 2024. Available at: https://covid19criticalcare.com/protocol/i-recover-post-vaccine-treatment/

8. Chen H, McGowan EM, Ren N, et al. Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Biomark Insights . 2018 Jul 5;13:1177271918785130. PMID: 30013308.

9. Kurosawa Y, Nirengi S, Homma T, et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep . 2015 Jun 29;5:11601. PMID: 26118925.

10. Boros A, Lőrincz O, Pál S, et al. Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. Pharmacol Res Perspect . 2024 Jun;12(3):e1218. PMID: 38874490.